This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matherly, L. H. Articles by Goldman, I. D. Search for Related Content PubMed PubMed Citation Articles by Matherly, L. H. Articles by Goldman, I. D.

Antifolate Polyglutamylation and Competitive Drug Displacement at Dihydrofolate Reductase as Important Elements in Leucovorin Rescue in L1210 Cells¹

Departments of Medicine and Pharmacology, Medical College of Virginia, Richmond, Virginia 23298

Previous studies from this laboratory have shown that the addition of leucovorin to tumor cells dissociates methotrexate, but not methotrexate polyglutamates, from dihydrofolate reductase (L. H. Matherly, D. W. Fry, and I. D. Goldman, Cancer Res., 43: 2694–2699, 1983). To further assess the importance of these interactions to leucovorin rescue, antifolate growth inhibition toward L1210 cells in the presence of leucovorin was correlated with the metabolism of (6S)-5-formyl tetrahydrofolate to dihydrofolate as a measure of dihydrofolate reductase activity. Growth inhibition (greater than 95%) by methotrexate (5–10 µM) following its intracellular polyglutamylation during a 3-h preexposure, or by continuous treatment with high levels of the lipophilic antifolate, trimetrexate (1 µM), was only slightly diminished by 10 µM leucovorin (15–25%). High-pressure liquid chromatographic analyses of the derivatives formed from radiolabeled (6S)-5-formyl tetrahydrofolate under these conditions showed an incomplete conversion to dihydrofolate and metabolism to predominantly 10-formyl tetrahydrofolate. Neither of the antifolates interfered appreciably with the metabolism of the folate derivatives to polyglutamates. Growth inhibition in the presence of leucovorin correlated with the accumulation of dihydrofolate (1.5–2.2 nmol) from radiolabeled (6S)-5-formyl tetrahydrofolate, reflecting continued suppression of dihydrofolate reductase activity at these drug concentrations. With lower equitoxic levels of the trimetrexate (7.5 nM), the provision of leucovorin allowed for a restoration of cell growth to a level greater than 90% of control. Under these conditions, control levels of dihydrofolate (0.2 nmol) were formed from radiolabeled cofactor, consistent with sustained dihydrofolate reductase activity.

These findings support a role for the activation of dihydrofolate reductase as an important component of the reversal of the effects of diaminoantifolates by leucovorin, presumably by a competitive displacement of drug from the enzyme. Since no displacement occurs in cells which have accumulated methotrexate polyglutamates, or in the presence of high levels of trime-trexate, it appears that the concentration of unbound drug within cells is a significant determinant of the extent of this competitive binding interaction. From these considerations, the high levels of methotrexate polyglutamates that accumulate in sensitive tumors relative to bone marrow and gastrointestinal cells would appear to represent an important factor for the selectivity of leucovorin rescue in vivo.

¹ Supported by Research Grant CA-16906 and Training Grant CA-09340 from the National Cancer Institute, NIH.

² Recipient of a Junior Faculty Research Award from the American Cancer Society.

Received 6/27/85. Revised 10/ 9/85. Accepted 10/11/85.

This article has been cited by other articles:

				M. Aghi, C. M. Kramm, and X. O. Breakefield Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo J Natl Cancer Inst, July 21, 1999; 91(14): 1233 - 1241. [Abstract] [Full Text] [PDF]

				M. Chow and H. Rubin Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin PNAS, April 14, 1998; 95(8): 4550 - 4555. [Abstract] [Full Text] [PDF]